Isatuximab plus carfilzomib and dexamethasone in Japanese patients with relapsed multiple myeloma: subgroup analysis of the randomized, open label, phase 3 IKEMA study.

Tadao IshidaShigeki ItoJunji TanakaMichihiro UchiyamaYawara KawanoPhilippe MoreauThomas MartinMarie-Laure RisseKeisuke TadaKenshi SuzukiKenichi Ishizawa

Published in: Japanese journal of clinical oncology (2022)

Keyphrases

multiple myeloma
open label
phase iii
phase ii
clinical trial
double blind
acute lymphoblastic leukemia
acute myeloid leukemia
phase ii study
low dose
diffuse large b cell lymphoma
high dose
study protocol
squamous cell carcinoma
hodgkin lymphoma
radiation therapy
locally advanced